Francesco Nicoldi
The COVID-19 pandemic caused by SARS-CoV-2 has posed distinct challenges for individuals undergoing chemotherapy, as their compromised immune systems render them susceptible to severe infections. This article explores the evolution of SARS-CoV-2 within this specific patient group, shedding light on the intricate relationship between viral dynamics, immune suppression due to chemotherapy, and potential implications for treatment strategies. Chemotherapy-induced immune suppression prolongs viral persistence and replication, possibly fostering the accumulation of mutations and emergence of new variants. Antiviral treatments exert selective pressure on the virus, potentially driving the development of variants with altered characteristics. This article underscores the importance of ongoing research to elucidate the evolutionary dynamics of SARS-CoV-2 in chemotherapy patients, providing insights into disease progression, transmissibility, and treatment efficacy. By deciphering these complexities, tailored therapeutic interventions can be designed to effectively manage COVID-19 in this vulnerable population.